Just after midnight on the morning of Aug. 7, President Trump’s sweeping “reciprocal” tariffs took effect on dozens of international trading partners, marking another dramatic escalation of the administration’s “America First” trading policy.
Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
President Trump signed H.R.1, Republicans’ “big, beautiful” reconciliation bill, into law on July 4, 2025. Starting from that date, the law lays out effective dates and implementation dates for its numerous health provisions over the next few years, and beyond.
AMCP comments on Trump Administration demands for manufacturers to take action on Most-Favored-Nation pricing scheme
H.R. 1, or the Big Beautiful Bill, has brought substantial change to the managed care pharmacy landscape, particularly for managed care organizations (MCOs) with managed Medicaid lines of business.
Today, Senator Josh Hawley (R-MO) introduced legislation that would rollback some of the impending cuts to federal Medicaid funding as mandated by H.R. 1.
HealthyWomen, members of its HPV Coalition and additional stakeholders are writing the Advisory Committee on Immunization Practices (ACIP) regarding the upcoming June ACIP meeting June 25-27, 2025, docket number - CDC-2005-0024.
On July 4, President Trump signed H.R. 1, often referred to as the One Big Beautiful Bill Act, into law.
The Department of Health and Human Services (HHS) sent out an RFI. AMCP provided a response which aims to promote precision medicine through a reconsideration of the "14 Day Rule".
On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.
H.R. 1 will result in less preventive care and more preventable emergency room visits, increasing costs for everyone across the health care system and threatening hospitals with closure, which will further reduce access to critical care for American patients.
In Kennedy v. Braidwood Management, Inc., the plaintiffs challenged the constitutionality of the USPSTF, arguing that USPSTF members should be considered “principal officers” under the Appointments Clause and, therefore, must be appointed by the President and confirmed by the Senate.
As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.
